Regeneron Pharmaceuticals Inc. buy Sanford C. Bernstein
Start price
12.03.24
/
50%
€887.00
Target price
12.03.25
€1,030.6
Performance (%)
0.25%
Price
03.05.24
€889.20
Summary
This prediction is currently active. The BUY prediction by Sanford_C__Bernstein for Regeneron Pharmaceuticals Inc. is nearly unchanged. This prediction currently runs until 12.03.25. The prediction end date can be changed by Sanford_C__Bernstein at any time. Sanford_C__Bernstein has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Regeneron Pharmaceuticals Inc. | 7.756% | 7.756% |
| iShares Core DAX® | -0.922% | -1.078% |
| iShares Nasdaq 100 | 0.371% | -0.556% |
| iShares Nikkei 225® | 2.224% | -2.825% |
| iShares S&P 500 | -0.026% | -0.788% |
Comments by Sanford_C__Bernstein for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is now covered by analysts at Sanford C. Bernstein. They set an "outperform" rating and a $1,125.00 price target on the stock.
Ratings data for REGN provided by MarketBeat